close

Enter

Log in using OpenID

Recombinant Therapeutic Antibodies and Proteins Market

embed
Recombinant Therapeutic Antibodies and Proteins
Market - Size, Share, trends, and Forecast to 2026
Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including noncovalent binders. These proteins are highly effective and serve as modernized treatment for rare
as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by
supporting a specifically targeted therapeutic process by compensating the deficiency of an
essential protein. Recombinant proteins have gained significant traction for therapeutic
applications and the number of proteins either launched or approved into clinical trials has
continually increased over the past two decades. According to the National Center for
Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA)
approved over 140 recombinant therapeutic proteins for human use and several hundred are
currently in development. Majority of these proteins are recombinant monoclonal antibodies.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1981
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 91.2
billion in 2017, and is expected to witness a robust CAGR of 12.2% over the forecast period
(2018 – 2026).
Market Dynamics
Recombinant therapeutic proteins and antibodies have gained high traction in clinical
applications. Due to development of antibody-based therapeutics, mammalian expression systems
have experienced a major boost and microbial expression systems continue to be widely used in
industries, which in turn will fuel growth of the market. However, variations in production
methods of therapeutic antibodies can lead to differences in their structure, based on the
selection of recombinant procedure. Most protein therapeutics available in the market are
recombinant and majority of them are in clinical trials for therapy of immune disorders,
cancers, infections, and other diseases. Various engineered proteins, including multi-specific
fusion proteins, bi-specific monoclonal antibodies (mAbs) and mAbs conjugated small molecule
drugs, and proteins with optimized pharmacokinetics are under development.
Advancements in recombinant therapeutic drugs are expected to bolster the recombinant
therapeutic antibodies and proteins market growth
Integration of novel approaches and strategies to modify protein drug products is an important
aspect. Advancements in recombinant protein technologies have allowed drug manufacturers and
developers to adjust required functional characteristics of proteins of interest while maintaining
product efficacy and safety.
Various recombinant technologies are currently in use to increase the half-life, functionality,
and targeting of novel therapeutic protein drugs and increase product purity and volume. For
instance, protein conjugation and derivatization methods, including albumin-fusion15,
PEGylation and Fc-fusion are currently being used to extend a drug’s circulating half-life.
Report includes chapters which deeply display the following deliverable about industry :
• Recombinant Therapeutic Antibodies and Proteins Market Research Objective and Assumption
• Recombinant Therapeutic Antibodies and Proteins Market Purview - Report Description,
Executive Summary, and Coherent Opportunity Map (COM)
• Recombinant Therapeutic Antibodies and Proteins Market Dynamics, Regulations, and Trends
Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New
system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Recombinant Therapeutic Antibodies and Proteins Market, By Regions
• Recombinant Therapeutic Antibodies and Proteins Market Competition by Manufacturers
including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales
Area and Product Type.
• Recombinant Therapeutic Antibodies and Proteins Market Manufacturers Profiles/Analysis
including Company Basic Information, Manufacturing Base and Its Competitors.
• Recombinant Therapeutic Antibodies and Proteins Market Manufacturing Cost Analysis
including Key Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Recombinant Therapeutic Antibodies and Proteins Market Forecast including Production,
Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1981
Major players operating in the global recombinant therapeutic antibodies and proteins market
include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche,
Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Alex Huge
Alex Huge371   document Email
1/--pages
Report inappropriate content